• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Knowledge, Attitude and Practice about Glucagon-like Peptide-1 Receptor Agonist Among the Physicians of Prince Mohammed bin Abdulaziz Hospital & Primary Health Care, National Guard, Saudi Arabia
  • VIEWS 75
  • PDF 38

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v24.i1.71

Year: 2025, Volume: 24, Issue: 1, Pages: 36-44

Original Article

Knowledge, Attitude and Practice about Glucagon-like Peptide-1 Receptor Agonist Among the Physicians of Prince Mohammed bin Abdulaziz Hospital & Primary Health Care, National Guard, Saudi Arabia

Meshari A Turjoman1,∗, Amani Mahrous1, Ahmed A Ozbuk1, Raghad M Alhujaili2, Hessan T Bagasi1, Khulood A Alsiary3

1Family Medicine Department, National Guard Health Affairs, Prince Mohammad ben Abdul-Aziz Hospital, Madinah, KSA
2Family Medicine, Madinah Health Cluster, Madinah, KSA
3Family Medicine Department, National Guard Health Affairs, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, KSA

*Corresponding Author
Email: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a newly approved medication in the management of Diabetes Mellitus. GLP-1RA has potential adverse effects and risks such as gastrointestinal symptoms, pancreatitis, and thyroid cell neoplasia, respectively. A cross-sectional study, through a validated questionnaire with fixed answers, was utilized to assess the physician’s response regarding GLP-1RA. Participants were Saudi females, younger than 35 years. Physicians with variable educational degrees were included. In regard to prescription authority, it was limited to only around 25.5% of the treating physicians. Knowledge items were scored correctly by 77.2% of participants. And around half of the group 51.6% showed a positive attitude toward GLP-1RA, reflected as strongly agree and agree in the questionnaire. And only 55.2% of participants showed good practice in terms of utilization of GLP-1RA. These findings suggest that continuous professional development and well-organized training programs are crucial to bridge knowledge gaps and refine practice patterns.

Keywords: Knowledge, Attitude, Practice, Glucagon-like peptide-1 receptor agonist, Physicians

References

  1. Dawish M, Robert A, Braham R, Hayek A, Saeed A, Ahmed R. Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. Current Diabetes Reviews. 2016;12(4):359–368. Available from: https://doi.org/10.2174/1573399811666150724095130
  2. Wołos-Kłosowicz K, Matuszewski W, Rutkowska J, Krankowska K, Bandurska-Stankiewicz E. Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? Journal of Clinical Medicine. 2022;11(20):1–13. Available from: https://doi.org/10.3390/jcm11206183
  4. Mullan R, Montori V, Shah N, Christianson J, Bryant S, Guyatt G. The diabetes mellitus medication choice decision aid: a randomized trial. Archives of internal medicine. 2009;169(17):1560–1568. Available from: https://doi.org/10.1001/archinternmed.2009.293
  7. Nauck M, Niedereichholz U, Ettler R. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology-Legacy Content . 1997;273(5 Pt 1):E981–E988. Available from: http://dx.doi.org/10.1152/ajpendo.1997.273.5.E981
  8. Maljaars J, Peters HPF, Masclee AM. Review article: the gastrointestinal tract: neuroendocrine regulation of satiety and food intake. Alimentary Pharmacology & Therapeutics. 2007;26(Suppl 2):241–250. Available from: https://doi.org/10.1111/j.1365-2036.2007.03550.x
  9. Gutniak M, Orskov C, Holst J, Ahre´n B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New England Journal of Medicine. 1992;326(20):1316–1322. Available from: https://doi.org/10.1056/nejm199205143262003
  11. Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. International Journal of Clinical Practice. 2010;64(10):1402–1414. Available from: https://doi.org/10.1111/j.1742-1241.2010.02465.x
  12. Kristensen S, Rørth R, Jhund P, Docherty K, Sattar N, Preiss D. Cardiovascular, mortality, and kidney outcomes with GLP- 1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology. 2019;7(10):776–785. Available from: https://doi.org/10.1016/s2213-8587(19)30249-9
  13. Wołos-Kłosowicz K, Matuszewski W, Rutkowska J, Krankowska K, Bandurska-Stankiewicz E. Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? Journal of Clinical Medicine. 2022;11(20):1–13. Available from: https://doi.org/10.3390/jcm11206183
  14. Solanki JD, Sheth NS, Shah CJ, Mehta HB. Knowledge, attitude, and practice of urban Gujarati type 2 diabetics: Prevalence and impact on disease control. Journal of Education and Health Promotion. 2017;6(1):1–7. Available from: https://doi.org/10.4103/jehp.jehp_101_15
  15. Hazra A, Choudhury S, Das S. Survey of knowledge-attitude-practice concerning insulin use in adult diabetic patients in eastern India. Indian Journal of Pharmacology. 2014;46(4):425–429. Available from: https://doi.org/10.4103/0253-7613.135957
  17. Wahab F, Abdullah S, Abdullah J, Jaafar H, Noor S, Mohammad W, et al. Updates on Knowledge, Attitude and Preventive Practices on Tuberculosis among Healthcare Workers. Malaysian Journal of Medical Sciences. 2016;23(6):25–34. Available from: https://doi.org/10.21315/mjms2016.23.6.3
  18. Vaduganathan M, Patel R, Singh A, Mccarthy C, Qamar A, Januzzi J, et al. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. Journal of American College of Cardiology. 2019;73(12):1596–1598. Available from: https://doi.org/10.1016/j.jacc.2019.01.029
  19. Slater T, Drozd M, Palin V, Bowles C, Waduud M, Khatib R, et al. Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists’ attitudes and practice. European Heart Journal: Cardiovascular Pharmacotherapy. 2020;6(3):194–196. Available from: https://doi.org/10.1093/ehjcvp/pvz058
  22. Farooqui M, Othman CN, Kanakal M. Knowledge, Attitudes, Practices (KAP) of Complementary & Alternative Medicine (CAM) Amongst Diploma Pharmacy Students in Malaysia. The Open Conference Proceedings Journal. 2013;4(1):165. Available from: https://dx.doi.org/10.2174/2210289201304010165
  24. Gourgari E, Huerta‐-Saenz L, Tonyushkina KN, Rosolowsky ET, Guttmann‐Bauman I. Use of glucagon‐like peptide‐1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives. Pediatric Diabetes. 2021;22(6):872–875. Available from: https://dx.doi.org/10.1111/pedi.13234
  25. Kurevija T, Šojat D, Bosnić Z, Mujaj B, Varžić SC, Trtica LM. The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective. Journal of Clinical Medicine. 2024;13(6):1–19. Available from: https://dx.doi.org/10.3390/jcm13061617

Copyright

© 2024 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 23 March 2025

Year: 2025, Volume: 24, Issue: 1


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.